Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-Cloning

15 Apr 2022

Abstract excerpt

Improving productivity to reduce the cost of biologics manufacturing and ensure that therapeutics can reach more patients remains a major challenge faced by the biopharmaceutical industry. Chinese hamster ovary (CHO) cell lines are commonly prepared for biomanufacturing by single cell cloning post-transfection and recovery, followed by lead clone screening, generation of a research cell bank (RCB), cell culture...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Protein purification and stability
Share to Viral Infectious Diseases and Gene Expression in Insects

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35447733
DOI: 10.3390/bioengineering9040173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 18 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Titer in Late-Stage Mammalian Cell Culture Manufacturing by Re-CloningPMID 35447733Read ↗

Generation of reference cell lines, media, and a process platform for CHO cell biomanufacturingSemantic proximity Read ↗

Demonstration of a robust high cell density transient CHO platform yielding mAb titers of up to 2 g/L without medium exchangeSemantic proximity Read ↗

Rapid cGMP Manufacturing of COVID-19 monoclonal antibody using stable CHO cell poolsSemantic proximity Read ↗

Utilizing non-clonal CHO cell derived materials for preclinical studies of complex moleculesSemantic proximity Read ↗

High‐throughput and automation advances for accelerating single‐cell cloning, monoclonality and early phase clone screening steps in mammalian cell line development for biologics productionSemantic proximity Read ↗

Bioreactor scale up and protein product quality characterization of piggyBac transposon derived CHO poolsSemantic proximity Read ↗

Advances in recombinant antibody manufacturingSemantic proximity Read ↗

Towards maximum acceleration of monoclonal antibody development: Leveraging transposase-mediated cell line generation to enable GMP manufacturing within 3 months using a stable poolSemantic proximity Read ↗

When will we have a clone? An industry perspective on the typical CLD timelineSemantic proximity Read ↗

Diversity in host clone performance within a <scp>C</scp> hinese hamster ovary cell lineSemantic proximity Read ↗

Impact of cell culture on recombinant monoclonal antibody product heterogeneitySemantic proximity Read ↗

A comparative analysis of recombinant Fab and full‐length antibody production in Chinese hamster ovary cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.